{"filing":{"accession_number":"0001437749-26-021038","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"crvo20260618c_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926021038/crvo20260618c_8k.htm"},"events":[{"id":11695,"run_id":10278,"accession_number":"0001437749-26-021038","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"CervoMed received a notice of allowance from the USPTO for a patent protecting neflamapimod for treating dementia with Lewy bodies, extending intellectual property protection to 2042. While patent issuances are generally positive developments for biopharmaceutical companies, this disclosure does not fit cleanly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The patent protection is material to investors assessing the company's competitive position and product pipeline, warranting classification as other_material.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8349,"accession_number":"0001437749-26-021038","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"CervoMed received a notice of allowance from the USPTO for a patent protecting neflamapimod for treating dementia with Lewy bodies, extending intellectual property protection to 2042. While patent issuances are generally positive developments for biopharmaceutical companies, this disclosure does not fit cleanly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The patent protection is material to investors assessing the company's competitive position and product pipeline, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:23:06.221402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8349,"accession_number":"0001437749-26-021038","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"CervoMed received a notice of allowance from the USPTO for a patent protecting neflamapimod for treating dementia with Lewy bodies, extending intellectual property protection to 2042. While patent issuances are generally positive developments for biopharmaceutical companies, this disclosure does not fit cleanly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The patent protection is material to investors assessing the company's competitive position and product pipeline, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:23:06.221402+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18"}]}